Watson beats Cephalon's cheeky, fizzy fentanyl patents
This article was originally published in Scrip
Executive Summary
A federal judge in Delaware has sided with Watson Pharmaceuticals and ruled that its version of Cephalon's Fentora (fentanyl buccal tablets), an effervescent formulation used to treat breakthrough pain in cancer patients, does not infringe two US patents, and that the patents are invalid for lack of enablement.